

Gerasimos S Filippatos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5095813/publications.pdf>

Version: 2024-02-01

339
papers

51,814
citations

2962

96
h-index

1875

215
g-index

341
all docs

341
docs citations

341
times ranked

31822
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.4	50
2	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	1.2	5
3	Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 65-70.	0.7	4
4	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022, 243, 11-14.	1.2	2
5	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLP-1 RA</sc> treatment: A subgroup analysis from the <sc>FIDELIO-DKD</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	2.2	41
6	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.4	73
7	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
8	Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 890-902.	1.1	13
9	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
10	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
11	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	5.5	29
12	Patiomer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the <sc>DIAMOND</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	2.9	32
13	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
14	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
15	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
16	Early benefit with empagliflozin in heart failure with preserved ejection fraction: <sc>insights from the EMPEROR-Preserved trial</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.	2.9	26
17	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <sc>EMPEROR-Reduced</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	2.9	32
18	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <sc>REPORT-HF</sc> registry. <i>European Journal of Heart Failure</i> , 2022, 24, 645-652.	2.9	18

#	ARTICLE	IF	CITATIONS
19	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
20	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2022, 24, 406-420.	2.9	22
21	Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	2.9	6
22	Robustness of outcomes in trials evaluating sodium-glucose cotransporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
23	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20
24	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the ESC-HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
25	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
26	Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection. <i>European Journal of Heart Failure</i> , 2022, 24, 727-729.	2.9	28
27	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
28	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	1.0	144
29	Rising trends in Takotsubo syndrome during the COVID-19 pandemic: A single center experience. <i>Hellenic Journal of Cardiology</i> , 2022, , .	0.4	1
30	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	2.9	15
31	Skeletal muscle alterations and exercise intolerance in heart failure with preserved ejection fraction patients: ultrasonography assessment of diaphragm and quadriceps. <i>European Journal of Heart Failure</i> , 2022, 24, 729-731.	2.9	5
32	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
33	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	2.9	23
34	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 2212-2220.	1.0	10
35	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137.	1.2	36
36	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2224-2234.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Decongestion, kidney injury and prognosis in patients with acute heart failure. International Journal of Cardiology, 2022, 354, 29-37.	0.8	6
38	Endothelial glycocalyx integrity in oncological patients. International Journal of Cardiology, 2022, 360, 62-67.	0.8	2
39	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
40	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, 2022, 24, 1009-1019.	2.9	6
41	Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544.	2.9	10
42	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure, 2022, 24, 2131-2139.	2.9	8
43	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. JACC: Heart Failure, 2022, 10, 651-661.	1.9	9
44	Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol. Clinical and Experimental Emergency Medicine, 2022, 9, 140-145.	0.5	4
45	Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. European Journal of Heart Failure, 2022, 24, 1460-1466.	2.9	12
46	Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	2.9	21
47	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	1.0	39
48	Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1327-1345.	2.9	42
49	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	1.2	21
50	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236.	1.8	8
51	Drug development in oncology and devices – lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262.	1.7	0
52	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222
53	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation, 2021, 143, 310-321.	1.6	168
54	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 2021, 143, 540-552.	1.6	171

#	ARTICLE	IF	CITATIONS
55	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
56	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
57	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 533-541.	0.7	11
58	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
59	Is acute heart failure a distinctive disorder? An analysis from BIOSSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
60	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25.	1.4	11
61	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	2.9	10
62	Arrhythmias in cancer: rhythm is gonna get you!. <i>European Journal of Heart Failure</i> , 2021, 23, 154-156.	2.9	8
63	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	1.0	96
64	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	1.0	114
65	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	1.0	11
66	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	1.4	20
67	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	1.2	105
68	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	2.9	9
69	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	1.2	94
70	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	1.0	78
71	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
72	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	2.9	70

#	ARTICLE	IF	CITATIONS
73	Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1238-1240.	2.9	2
74	Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1122-1130.	2.9	14
75	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	0.7	362
76	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 349-359.	1.9	14
77	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	2.9	160
78	FC 021 EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
79	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3
80	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 457</i>	0.7	10
81	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3168-3179.	1.4	33
82	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
83	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 854-871.	2.9	105
84	FC 090 EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
85	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. <i>American Journal of Cardiology</i> , 2021, 147, 70-79.	0.7	7
86	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2021, 23, 1170-1181.	2.9	11
87	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	1.0	38
88	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1529-1538.	2.9	30
89	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. <i>Journal of Cardiac Failure</i> , 2021, 27, 727-743.	0.7	29
90	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021, 89, 65-75.	1.0	18

#	ARTICLE	IF	CITATIONS
91	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
92	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , 2021, 23, 1250-1255.	2.9	17
93	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
94	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
95	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
96	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	2.9	32
97	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
98	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464.	1.0	33
99	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
100	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799.	2.9	21
101	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
102	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332.	1.2	55
103	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	1.2	52
104	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
105	Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". <i>Circulation</i> , 2021, 144, e202-e203.	1.6	7
106	Amended STRONG-HF study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	2.9	8
107	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
108	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117

#	ARTICLE	IF	CITATIONS
109	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
110	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
111	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	1.9	7
112	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
113	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
114	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
115	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 401.	3.0	51
116	Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study. <i>European Journal of Heart Failure</i> , 2020, 22, 251-263.	2.9	19
117	Sex and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
118	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
119	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	2.9	47
120	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	2.9	15
121	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
122	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
123	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. <i>Journal of Medical Economics</i> , 2020, 23, 1401-1408.	1.0	1
124	Heart failure in Greece: The Hellenic National Nutrition and Health Survey (HNNHS). <i>Hellenic Journal of Cardiology</i> , 2020, 62, 315-317.	0.4	2
125	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	1.9	12
126	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2393-2398.	2.9	19

#	ARTICLE	IF	CITATIONS
127	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	6.3	425
128	Vitamin B12 deficiency in heart failure: another "brick in the wall". <i>Hellenic Journal of Cardiology</i> , 2020, 61, 338-340.	0.4	0
129	Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 669-679.	1.2	41
130	HELLENIC Registry on Myocarditis Syndrome on behalf of Hellenic Heart Failure Association: The HERMES-HF Registry. <i>ESC Heart Failure</i> , 2020, 7, 3676-3684.	1.4	5
131	Cardioprotective stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3345-3354.	1.4	23
132	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	13.9	1,148
133	Ten lessons from the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1991-1993.	2.9	6
134	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 2972-2982.	1.4	9
135	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
136	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , 2020, 396, 819-829.	6.3	816
137	Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. <i>European Heart Journal</i> , 2020, 41, 3398-3401.	1.0	20
138	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. <i>Nutrients</i> , 2020, 12, 2541.	1.7	16
139	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
140	Assessing frailty in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2134-2137.	2.9	6
141	Epidemiology, pathophysiology and contemporary management of cardiogenic shock: A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1315-1341.	2.9	244
142	Sodium-glucose co-transporter 2 inhibitors: "a tale of two sisters"™, diabetes and heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1259-1262.	2.9	2
143	Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 305.	0.8	6
144	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65

#	ARTICLE	IF	CITATIONS
145	Heart failure in the course of a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 1755-1758.	2.9	5
146	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. <i>European Journal of Heart Failure</i> , 2020, 22, 763-774.	2.9	24
147	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	2.9	21
148	Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 7, 321-323.	1.4	9
149	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23
150	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	2.9	100
151	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	0.7	46
152	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020, 8, e411-e422.	2.9	104
153	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
154	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	2.9	50
155	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 906-910.	2.9	5
156	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
157	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
158	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005.	2.9	71
159	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
160	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3298-3309.	1.4	76
161	Cardio-oncology services during the COVID-19 pandemic: practical considerations and challenges. <i>European Journal of Heart Failure</i> , 2020, 22, 929-932.	2.9	4
162	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20

#	ARTICLE	IF	CITATIONS
163	Heart failure guidelines implementation: Lifting barriers with registries and networks. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 41-42.	0.5	2
164	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	2.9	34
165	Effects of Seralaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	13.9	174
166	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	2.9	155
167	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	2.9	205
168	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	1.4	22
169	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	2.9	9
170	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
171	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
172	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
173	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	2.9	490
174	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	2.9	40
175	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	2.9	446
176	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy. <i>ESC Heart Failure</i> , 2019, 6, 621-628.	1.4	19
177	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <i>Journal of Cardiac Failure</i> , 2019, 25, 654-665.	0.7	23
178	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	2.9	172
179	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
180	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	2.9	86

#	ARTICLE	IF	CITATIONS
181	Vaccination in Patients With Heart Disease. How Long Should We Wait? Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 516.	0.4	0
182	Rationale and design of the AFFIRMâ€”AHF trial: a randomised, doubleâ€”blind, placeboâ€”controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€”deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	2.9	42
183	Potential Utility of Neurosonology in Paroxysmal Atrial Fibrillation Detection in Patients with Cryptogenic Stroke. <i>Journal of Clinical Medicine</i> , 2019, 8, 2002.	1.0	8
184	Bâ€”type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1553-1560.	2.9	29
185	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
186	Association with outcomes and response to treatment of trimethylamine Nâ€”oxide in heart failure: results from BIOSTATâ€”CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	2.9	68
187	Medication dosing for heart failure with reduced ejection fraction â€” opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296.	2.9	57
188	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	2.9	138
189	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€”who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	2.9	107
190	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
191	Vaccination in Heart Failure: An Approach to Improve Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 697-699.	0.4	2
192	Renin inhibition in heart failure and diabetes: the real story. <i>European Journal of Heart Failure</i> , 2018, 20, 149-151.	2.9	7
193	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	1.4	50
194	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
195	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	2.9	128
196	Proteomic diversity of highâ€”density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
197	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	0.8	2
198	Potassium and the use of reninâ€”angiotensinâ€”aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€”CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57

#	ARTICLE	IF	CITATIONS
199	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
200	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018, 39, 17-25.	1.0	111
201	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113
202	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018, 20, 1081-1099.	2.9	57
203	Usefulness of Proneurotensin to Predict Cardiovascular and All-Cause Mortality in a United States Population (from the Reasons for Geographic and Racial Differences in Stroke Study). <i>American Journal of Cardiology</i> , 2018, 122, 26-32.	0.7	9
204	Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factor in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1162-1163.	2.9	2
205	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	2.9	317
206	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRVO27: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	1.5	27
207	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	2.9	69
208	Ups and downs in heart failure: the case of proteomics. <i>European Journal of Heart Failure</i> , 2018, 20, 63-66.	2.9	6
209	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
210	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
211	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	1.0	171
212	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14,964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	1.0	189
213	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	0.8	140
214	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	2.9	555
215	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
216	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta β -adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta β -left ventricular hypertrophy (Beta β -LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	1.4	29

#	ARTICLE	IF	CITATIONS
217	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
218	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
219	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
220	Cardioprotective cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw543.	1.0	148
221	A multimarker multi-time point based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	2.9	81
222	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	1.5	8
223	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	2.9	19
224	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
225	Duration of paroxysmal atrial fibrillation in cryptogenic stroke is not associated with stroke severity and early outcomes. <i>Journal of the Neurological Sciences</i> , 2017, 376, 191-195.	0.3	9
226	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
227	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1242-1254.	2.9	339
228	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	2.9	104
229	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	1.0	102
230	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	2.9	183
231	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 206-217.	0.6	39
232	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2017, 136, e137-e161.	1.6	2,130
233	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 776-803.	1.2	2,256
234	Reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	2.9	84

#	ARTICLE	IF	CITATIONS
235	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	1.2	10
236	Understanding worsening heart failure as a therapeutic target: another step forward?. <i>European Journal of Heart Failure</i> , 2017, 19, 996-1000.	2.9	1
237	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017, 19, 821-836.	2.9	252
238	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017, 19, 1520-1529.	2.9	89
239	How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2897-2900.	1.2	10
240	Surrogate endpoints in heart failure: (once again) use with caution. <i>European Journal of Heart Failure</i> , 2017, 19, 563-565.	2.9	0
241	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	1.0	285
242	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	1.2	9
243	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1574-1585.	2.9	568
244	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
245	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	6.1	525
246	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	2.9	115
247	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
248	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, 868-875.	0.7	159
249	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
250	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular only pacing. <i>European Journal of Heart Failure</i> , 2017, 19, 950-957.	2.9	33
251	Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2017, 4, 312-318.	1.4	22
252	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 1025.	3.0	280

#	ARTICLE	IF	CITATIONS
253	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	1.5	17
254	Rationale for and design of the <sc>TRUEâ€œAHF</sc> trial: the effects of ularitide on the shortâ€œterm clinical course and longâ€œterm mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	2.9	31
255	Patient engagement. <i>European Heart Journal</i> , 2017, 38, 3114-3115.	1.0	13
256	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <sc>BIOSTATâ€œCHF</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
257	MP415 EFFECT OF INTRAVENOUS IRON THERAPY WITH FERRIC CARBOXYMALTOSE ON OUTCOMES IN IRON-DEFICIENT PATIENTS WITH RENAL DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF FOUR RANDOMIZED, DOUBLE-BLIND TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii581-iii581.	0.4	1
258	European Society of Cardiology Heart Failure Longâ€œTerm Registry (<sc>ESCâ€œHFâ€œLT</sc>): 1â€œyear followâ€œup outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016, 18, 613-625.	2.9	538
259	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 859-868.	2.9	36
260	Effects of intravenous iron therapy in ironâ€œdeficient patients with systolic heart failure: a metaâ€œanalysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016, 18, 786-795.	2.9	270
261	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	1.9	49
262	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	0.7	12
263	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880.	1.9	58
264	Reframing the association and significance of coâ€œmorbidity in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 744-758.	2.9	169
265	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 8-27.	2.9	835
266	Congestive Heart Failure Cardiopoietic Regenerative Therapy (<sc>CHART</sc>â€œ1) trial design. <i>European Journal of Heart Failure</i> , 2016, 18, 160-168.	2.9	77
267	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	2.9	455
268	Clinical development plan for regenerative therapy in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 142-144.	2.9	11
269	Heart failure and kidney dysfunction: epidemiology, mechanisms and management. <i>Nature Reviews Nephrology</i> , 2016, 12, 610-623.	4.1	422
270	Structured discharge instructions for hospitalized heart failure patients to improve guideline implementation and patient outcomes. <i>International Journal of Cardiology</i> , 2016, 220, 143-145.	0.8	3

#	ARTICLE	IF	CITATIONS
271	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1420-1431.	1.2	85
272	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	1.0	274
273	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 271-305.	0.9	102
274	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	2.9	149
275	Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. <i>European Journal of Heart Failure</i> , 2016, 18, 822-829.	2.9	28
276	Diet and Exercise for Obese Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2618.	3.8	0
277	Positive emotions and Takotsubo syndrome: "happy heart" or "Diagoras" syndrome?. <i>European Heart Journal</i> , 2016, 37, 2821-2822.	1.0	8
278	Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	2.9	193
279	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
280	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	1.5	16
281	ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients. <i>European Journal of Heart Failure</i> , 2015, 17, 631-638.	2.9	69
282	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315
283	Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	2.9	143
284	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	2.9	86
285	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	2.9	110
286	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	2.9	60
287	Overcoming the ethnic differences in patients hospitalized for heart failure: is there a need for international harmonization of clinical practice guidelines?. <i>European Journal of Heart Failure</i> , 2015, 17, 755-757.	2.9	5
288	Pulmonary Oedema Therapeutic Targets. <i>Cardiac Failure Review</i> , 2015, 1, 38.	1.2	12

#	ARTICLE	IF	CITATIONS
289	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
290	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	0.7	22
291	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	1.9	68
292	Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. <i>International Journal of Cardiology</i> , 2015, 182, 74-76.	0.8	15
293	Risk of Heart Failure and Death After Prolonged Smoking Cessation. <i>Circulation: Heart Failure</i> , 2015, 8, 694-701.	1.6	57
294	Comparative evaluation of Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scoring systems in patients admitted to the cardiac intensive care unit. <i>Journal of Critical Care</i> , 2015, 30, 752-757.	1.0	20
295	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles. <i>Journal of the American College of Cardiology</i> , 2015, 66, 278-307.	1.2	191
296	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions. <i>Journal of the American College of Cardiology</i> , 2015, 66, 308-321.	1.2	413
297	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles. <i>European Heart Journal</i> , 2015, 36, 1851-1877.	1.0	37
298	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions. <i>European Heart Journal</i> , 2015, 36, 1878-1891.	1.0	133
299	International Registry to assess medical Practice with Longitudinal observation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015, 17, 527-533.	2.9	52
300	Usefulness of Colchicine to Reduce Perioperative Myocardial Damage in Patients Who Underwent On-Pump Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2015, 115, 1376-1381.	0.7	38
301	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	1.9	44
302	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. <i>European Heart Journal</i> , 2015, 36, 715-723.	1.0	69
303	In-hospital management of acute heart failure: Practical recommendations and future perspectives. <i>International Journal of Cardiology</i> , 2015, 201, 231-236.	0.8	31
304	Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction. <i>Circulation</i> , 2015, 132, 1395-1403.	1.6	208
305	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. <i>International Journal of Cardiology</i> , 2015, 201, 215-219.	0.8	32
306	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	3.8	288

#	ARTICLE	IF	CITATIONS
307	Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. <i>International Journal of Cardiology</i> , 2015, 180, 46-49.	0.8	35
308	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	1.0	902
309	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. <i>European Heart Journal</i> , 2014, 35, 2468-2476.	1.0	179
310	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	1.0	90
311	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, 4-25.	1.4	921
312	Insights Into Onco-Cardiology. <i>Journal of the American College of Cardiology</i> , 2014, 63, 945-953.	1.2	295
313	Renal dysfunction and heart failure: things are seldom what they seem. <i>European Heart Journal</i> , 2014, 35, 416-418.	1.0	58
314	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
315	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
316	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
317	Selenium contributes to myocardial injury and cardiac remodeling in heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 272-273.	0.8	18
318	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. <i>International Journal of Cardiology</i> , 2014, 172, 115-121.	0.8	96
319	Novel Biomarkers in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1654-1656.	1.2	7
320	Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, , 204887261452701.	0.4	20
321	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	1.4	5
322	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. <i>JACC: Heart Failure</i> , 2013, 1, 192-199.	1.9	107
323	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	1.2	397
324	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	1.0	419

#	ARTICLE	IF	CITATIONS
325	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
326	Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1267-1276.	2.9	130
327	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	1.0	139
328	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
329	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 899-906.	0.7	227
330	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	13.9	1,633
331	Cardiovascular Disease in Patients With Chronic Renal Impairment: Role of Natriuretic Peptides. <i>Congestive Heart Failure</i> , 2008, 14, 38-42.	2.0	7
332	Vasopressin Antagonists for the Treatment of Acute Decompensated Heart Failure: When, for Whom, for How Long, and on What Standard Therapy?. <i>Journal of Cardiac Failure</i> , 2008, 14, 648-650.	0.7	6
333	The Use of B-type Natriuretic Peptides in the Intensive Care Unit. <i>Congestive Heart Failure</i> , 2008, 14, 43-45.	2.0	2
334	Noninvasive ventilation improved dyspnea but did not reduce short-term mortality in acute cardiogenic pulmonary edema. <i>ACP Journal Club</i> , 2008, 149, 9.	0.1	1
335	Prognostic Value of Blood Urea Nitrogen in Patients Hospitalized With Worsening Heart Failure: Insights From the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) Study. <i>Journal of Cardiac Failure</i> , 2007, 13, 360-364.	0.7	138
336	An introduction to acute heart failure syndromes: definition and classification. <i>Heart Failure Reviews</i> , 2007, 12, 87-90.	1.7	61
337	Management with a pulmonary artery catheter did not reduce all-cause mortality in critically ill patients. <i>ACP Journal Club</i> , 2006, 144, 21.	0.1	1
338	Management with a pulmonary artery catheter did not reduce all-cause mortality in critically ill patients. <i>ACP Journal Club</i> , 2006, 144, 21.	0.1	0
339	Mitral Regurgitation Protects from Left Atrial Thrombogenesis in Patients with Mitral Valve Disease and Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 1863-1866.	0.5	15